Investors
NeOnc is steadfastly committed to its vision of developing new and better delivery technologies for CNS-based therapeutics. By doing so, it provides its investors with a partnership that offers increased security based on integrity and transparency.
Investor Information: NeOnc Technologies
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for CNS diseases, particularly those with poor prognoses and limited treatment options for patients, such as glioblastoma. Our patented platform technology is focused on bypassing the blood-brain barrier which could result in increased efficacy.
Our lead programs include:
- NEO100: A highly purified form of perillyl alcohol (POH) administered intranasally. NEO100 is currently in Phase II clinical trials for patients with recurrent malignant glioma (Grade IV, IDH1 mutant and Grade III Astrocytoma, IDH1 mutant) and malignant skull-based meningioma.
- NEO212: A novel drug delivery system combining the chemotherapeutic agent temozolomide (TMZ) for highly targeted treatment of primary and secondary brain tumors. NEO212 has completed preclinical testing and has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), authorizing progression to clinical trials. A Phase 1/2 trial for oral NEO212 started recruiting in late 2023, targeting patients with malignant gliomas and brain metastases.
Public Listing Information
NeOnc Technologies has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) as part of the process to become a publicly traded company. We’ve submitted the application to list under ticker symbol NTHI on NASDAQ Global Markets and are awaiting final approval.
Stay updated on our progress by subscribing to updates: